Skip to main content
Top
Published in: Investigational New Drugs 5/2020

01-10-2020 | Glioblastoma | PRECLINICAL STUDIES

Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells

Authors: Mona Oliveira, Lourenço Luis Botelho de Santana, José Claudio Serafim, Airam Oliveira Santos, Michelle Pereira Quintino, José Tiago Menezes Correia, Fabiano Damasceno, José Ricardo Sabino, Thiago Rubens Cardim Pires, Paulo Lucas Cerqueira Coelho, Giselle Pinto de Faria Lopes, Henning Ulrich, Silvia Lima Costa, Silvio Cunha

Published in: Investigational New Drugs | Issue 5/2020

Login to get access

Summary

Twelve multi-functional pyrrolizidinones, indolizidinones and pyrroliazepinones were prepared from formal aza-[3 + 2] and aza-[3 + 3] cycloadditions of five- to seven-membered heterocyclic enaminones as diverse ambident electrophiles. The antitumor activity of these alkaloid-like compounds was investigated through an initial screening performed on human glioblastoma multiform (GBM) cell lines (GL-15, U251), on murine glioma cells line (C6) and on normal glial cells. Of the compounds tested, the new pyrrolo[1,2a]azepinone, [ethyl (3-oxo-1,2-diphenyl-6,7,8,9-tetrahydro-3H-pyrrolo[1,2a]azepin-9a(5H)-yl)acetate] or (Compound-13) exhibited selective cytotoxic effects on GBM-temozolomide resistant cells. Compound-13 exerted dose-dependent cytotoxic activity by promoting arrest of cells in the G0/G1 phase of the cell cycle in the first 24 h. The apoptotic effect observed was in a time-dependent manner. Anti-migratory effect promoted by the treatment with compound-13 was also observed. Moreover, healthy mixed glial cell cultures from rat brain exhibited no cytotoxicity effect upon exposure to compound-13. Thus, the present study paves the way for the use of compound-13 as novel antitumor scaffold candidate for glioma cell therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ostrom QT et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology 17:1–62 Ostrom QT et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology 17:1–62
2.
go back to reference Tran B, Rosenthal MA (2010) Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 17:417–421PubMed Tran B, Rosenthal MA (2010) Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 17:417–421PubMed
3.
go back to reference Khosla D (2016) Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med 4:3–54 Khosla D (2016) Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med 4:3–54
4.
go back to reference Villà S, Balaňà C, Comas S (2014) Radiation and concomitant chemotherapy for patients with glioblastoma multiforme. Chin J Cancer 33:25–31PubMedPubMedCentral Villà S, Balaňà C, Comas S (2014) Radiation and concomitant chemotherapy for patients with glioblastoma multiforme. Chin J Cancer 33:25–31PubMedPubMedCentral
5.
go back to reference Hegi ME et al (2008) Correlation of O 6 -Methylguanine Methyltransferase ( MGMT ) promoter methylation with clinical outcomes in Glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol Soc 26:4189–4199 Hegi ME et al (2008) Correlation of O 6 -Methylguanine Methyltransferase ( MGMT ) promoter methylation with clinical outcomes in Glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol Soc 26:4189–4199
6.
go back to reference Banelli B et al (2015) The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle 14:3418–3429PubMedPubMedCentral Banelli B et al (2015) The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle 14:3418–3429PubMedPubMedCentral
7.
go back to reference Zheng M, Wang S, Liu Z, Xie L, Deng Y (2018) Development of temozolomide coated nano zinc oxide for reversing the resistance of malignant glioma stem cells. Mater Sci Eng C 83:44–50 Zheng M, Wang S, Liu Z, Xie L, Deng Y (2018) Development of temozolomide coated nano zinc oxide for reversing the resistance of malignant glioma stem cells. Mater Sci Eng C 83:44–50
8.
go back to reference Shi J, Dong B, Zhou P, Guan W, Peng Y (2017) Functional network analysis of gene-phenotype connectivity associated with temozolomide. Oncotarget 8:87554–87567PubMedPubMedCentral Shi J, Dong B, Zhou P, Guan W, Peng Y (2017) Functional network analysis of gene-phenotype connectivity associated with temozolomide. Oncotarget 8:87554–87567PubMedPubMedCentral
9.
go back to reference Verhaak RGW et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of Glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110PubMedPubMedCentral Verhaak RGW et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of Glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110PubMedPubMedCentral
10.
go back to reference Karkhanis M and Park J.I., (2010). Sp1 regulates Raf/MEK/ERK-induced p21CIP1 transcription in TP53-mutated cancer cells, Cell Signal, 64:645–662 Karkhanis M and Park J.I., (2010). Sp1 regulates Raf/MEK/ERK-induced p21CIP1 transcription in TP53-mutated cancer cells, Cell Signal, 64:645–662
11.
go back to reference Costa SL, Paillaud E, Fages C, Rochette-egly C, Plassat JL (2001) Effects of a novel synthetic retinoid on malignant glioma in vitro : inhibition of cell proliferation , induction of apoptosis and diferentiation. Eur J Cancer 37:520–530PubMed Costa SL, Paillaud E, Fages C, Rochette-egly C, Plassat JL (2001) Effects of a novel synthetic retinoid on malignant glioma in vitro : inhibition of cell proliferation , induction of apoptosis and diferentiation. Eur J Cancer 37:520–530PubMed
12.
13.
go back to reference Barth RF, Kaur B (2009) Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neuro-Oncol 94:299–312 Barth RF, Kaur B (2009) Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neuro-Oncol 94:299–312
14.
go back to reference Eisele G, Weller M (2013) Targeting apoptosis pathways in glioblastoma. Cancer Lett 332:335–345PubMed Eisele G, Weller M (2013) Targeting apoptosis pathways in glioblastoma. Cancer Lett 332:335–345PubMed
15.
go back to reference Barajas RF et al (2012) Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR imaging. Neuro-Oncology 14:942–954PubMedPubMedCentral Barajas RF et al (2012) Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR imaging. Neuro-Oncology 14:942–954PubMedPubMedCentral
16.
go back to reference Elkamhawy A et al (2015) Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). Eur J Med Chem 103:210–222PubMed Elkamhawy A et al (2015) Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). Eur J Med Chem 103:210–222PubMed
17.
go back to reference Cholewiñski G, Dzierzbicka K, Koodziejczyk AM (2011) Natural and synthetic acridines / acridones as antitumor agents : their biological activities and methods of synthesis, Pharmacol. Reports 1:7–12 Cholewiñski G, Dzierzbicka K, Koodziejczyk AM (2011) Natural and synthetic acridines / acridones as antitumor agents : their biological activities and methods of synthesis, Pharmacol. Reports 1:7–12
18.
go back to reference Fattorusso SOTE (2008) Modern alkaloids: Strucure, isolation, synthesis, and biology. Wilye, New York, VHC 29–33 Fattorusso SOTE (2008) Modern alkaloids: Strucure, isolation, synthesis, and biology. Wilye, New York, VHC 29–33
19.
go back to reference Robertson J, Stevens K (2014) Pyrrolizidine alkaloids. Nat Prod Rep 31:1721–1788PubMed Robertson J, Stevens K (2014) Pyrrolizidine alkaloids. Nat Prod Rep 31:1721–1788PubMed
20.
go back to reference Michael JP (2016) Simple indolizidine and quinolizidine alkaloids, alkaloids. Chem Biol 75:1–498 Michael JP (2016) Simple indolizidine and quinolizidine alkaloids, alkaloids. Chem Biol 75:1–498
21.
go back to reference Pilli RA, Rosso GB, de Oliveira Mda C (2010) The chemistry of Stemona alkaloids: an update. Nat Prod Rep 27:1908PubMed Pilli RA, Rosso GB, de Oliveira Mda C (2010) The chemistry of Stemona alkaloids: an update. Nat Prod Rep 27:1908PubMed
22.
go back to reference Alibes R, Figueredo M (2009) Strategies for the synthesis of Stemona alkaloids, European J. Org Chem 15:2421–2435 Alibes R, Figueredo M (2009) Strategies for the synthesis of Stemona alkaloids, European J. Org Chem 15:2421–2435
23.
go back to reference Chattopadhyay AK, Hanessian S (2015) Cyclic enaminones. Part I: stereocontrolled synthesis using diastereoselective and catalytic asymmetric methods. Chem Commun 51:16437–16449 Chattopadhyay AK, Hanessian S (2015) Cyclic enaminones. Part I: stereocontrolled synthesis using diastereoselective and catalytic asymmetric methods. Chem Commun 51:16437–16449
24.
go back to reference Hussaini SR, Chamala RR, Wang Z (2015) The Eschenmoser sulfide contraction method and its application in the synthesis of natural products. Tetrahedron 71:6017–6086 Hussaini SR, Chamala RR, Wang Z (2015) The Eschenmoser sulfide contraction method and its application in the synthesis of natural products. Tetrahedron 71:6017–6086
25.
go back to reference Seki H, Georg GI (2014) 2,3-dihydropyridin-4(1 H)-ones and 3-aminocyclohex-2-enones: synthesis, functionalization, and applications to alkaloid synthesis. Synlett 25:2536–2557 Seki H, Georg GI (2014) 2,3-dihydropyridin-4(1 H)-ones and 3-aminocyclohex-2-enones: synthesis, functionalization, and applications to alkaloid synthesis. Synlett 25:2536–2557
26.
go back to reference Ferraz HMC, Gonçalo ERS (2007) Recent preparations and synthetic applications of enaminones. Quim Nova 30:957–964 Ferraz HMC, Gonçalo ERS (2007) Recent preparations and synthetic applications of enaminones. Quim Nova 30:957–964
27.
go back to reference Cheng Y, Huang ZT, Wang MX (2004) Heterocyclic enamines: the versatile intermediates in the synthesis of heterocyclic compounds and natural products. Curr Org Chem 8:325–351 Cheng Y, Huang ZT, Wang MX (2004) Heterocyclic enamines: the versatile intermediates in the synthesis of heterocyclic compounds and natural products. Curr Org Chem 8:325–351
28.
go back to reference Negri G, Kascheres C, Kascheres AJ (2004) Recent development in preparation reactivity and biological activity of enaminoketones and enaminothiones and their utilization to prepare heterocyclic compounds. J Heterocyclic Chem 41:461–491 Negri G, Kascheres C, Kascheres AJ (2004) Recent development in preparation reactivity and biological activity of enaminoketones and enaminothiones and their utilization to prepare heterocyclic compounds. J Heterocyclic Chem 41:461–491
29.
go back to reference Kascheres CM (2003) The chemistry of enaminones, diazocarbonyls and small rings: our contribution. J Braz Chem Soc 14:945–969 Kascheres CM (2003) The chemistry of enaminones, diazocarbonyls and small rings: our contribution. J Braz Chem Soc 14:945–969
30.
go back to reference Elassar AZA, El-Khair AA (2003) Recent developments in the chemistry of enaminones. Tetrahedron 59:8463–8480 Elassar AZA, El-Khair AA (2003) Recent developments in the chemistry of enaminones. Tetrahedron 59:8463–8480
31.
go back to reference Ferraz HMC, Pereira FLC (2004) Síntese de enaminonas. Quim Nova 27:89–95 Ferraz HMC, Pereira FLC (2004) Síntese de enaminonas. Quim Nova 27:89–95
32.
go back to reference Chattopadhyay AK, Hanessian S (2015) Cyclic enaminones. Part II: applications as versatile intermediates in alkaloid synthesis. Chem Commun (Camb) 51:16450–16467 Chattopadhyay AK, Hanessian S (2015) Cyclic enaminones. Part II: applications as versatile intermediates in alkaloid synthesis. Chem Commun (Camb) 51:16450–16467
33.
go back to reference Pitanga BP, Nascimento RP, Silva VD, Costa SL (2012) The role of astrocytes in metabolism and neurotoxicity of the pyrrolizidine alkaloid monocrotaline, the main toxin of Crotalaria retusa. Front Pharmacol 3:1–7 Pitanga BP, Nascimento RP, Silva VD, Costa SL (2012) The role of astrocytes in metabolism and neurotoxicity of the pyrrolizidine alkaloid monocrotaline, the main toxin of Crotalaria retusa. Front Pharmacol 3:1–7
34.
go back to reference Barreto RA et al (2008) Monocrotaline pyrrol is cytotoxic and alters the patterns of GFAP expression on astrocyte primary cultures. Toxicol in Vitro 22:1191–1197PubMed Barreto RA et al (2008) Monocrotaline pyrrol is cytotoxic and alters the patterns of GFAP expression on astrocyte primary cultures. Toxicol in Vitro 22:1191–1197PubMed
35.
go back to reference Silva-Neto JP et al (2010) Genotoxicity and morphological changes induced by the alkaloid monocrotaline, extracted from Crotalaria retusa, in a model of glial cells. Toxicon 55:105–117PubMed Silva-Neto JP et al (2010) Genotoxicity and morphological changes induced by the alkaloid monocrotaline, extracted from Crotalaria retusa, in a model of glial cells. Toxicon 55:105–117PubMed
36.
go back to reference Cunha S, Filho RFDS, Saraiva KH, Azevedo-Santos AV, Menezes D (2013) Synthesis of multi-functionalized 1-azabicycles through MAOS acid catalyzed formal aza-[3+3] cycloaddition of heterocyclic enaminones with oxazolones. Tetrahedron Lett 54:3366–3370 Cunha S, Filho RFDS, Saraiva KH, Azevedo-Santos AV, Menezes D (2013) Synthesis of multi-functionalized 1-azabicycles through MAOS acid catalyzed formal aza-[3+3] cycloaddition of heterocyclic enaminones with oxazolones. Tetrahedron Lett 54:3366–3370
37.
go back to reference Cunha S, Damasceno F, Santos AO, Oliveira M, Costa SL (2017) One-step synthesis of 3 , 4-Diphenyl-2-pyrrolinones by Solvent-Free and Bi 2 O 3 -Catalyzed approaches and cytotoxicity screening against glioma. J Heterocyclic Chem 00:1–11 Cunha S, Damasceno F, Santos AO, Oliveira M, Costa SL (2017) One-step synthesis of 3 , 4-Diphenyl-2-pyrrolinones by Solvent-Free and Bi 2 O 3 -Catalyzed approaches and cytotoxicity screening against glioma. J Heterocyclic Chem 00:1–11
38.
go back to reference Coelho PLC et al (2016) The flavonoid apigenin from Croton betulaster Mull inhibits proliferation, induces differentiation and regulates the inflammatory profile of glioma cells, anticancer. Drugs 27:960–969 Coelho PLC et al (2016) The flavonoid apigenin from Croton betulaster Mull inhibits proliferation, induces differentiation and regulates the inflammatory profile of glioma cells, anticancer. Drugs 27:960–969
39.
go back to reference Chapdelaine JM (2011) MTT reduction - a tetrazolium-based colorimetric assay for cell survival and proliferation. Mol Devices1–6 Chapdelaine JM (2011) MTT reduction - a tetrazolium-based colorimetric assay for cell survival and proliferation. Mol Devices1–6
40.
go back to reference Sheldrick GM (2007) A short history of SHELX. Acta Crystallogr Sect A Found Crystallogr 64:112–122 Sheldrick GM (2007) A short history of SHELX. Acta Crystallogr Sect A Found Crystallogr 64:112–122
41.
go back to reference Nagasaka T, Inoue H, Hamaguchi F (1983) Synthesis of 5-Oxoindolizine derivatives. U L: reaction of ethyl Pyrrolidin-2-Ylideneacetate (an Enamine Ester) with acyclic C4.B- unsaturated carbonyl compounds. Heterocycles 20:1099–1107 Nagasaka T, Inoue H, Hamaguchi F (1983) Synthesis of 5-Oxoindolizine derivatives. U L: reaction of ethyl Pyrrolidin-2-Ylideneacetate (an Enamine Ester) with acyclic C4.B- unsaturated carbonyl compounds. Heterocycles 20:1099–1107
42.
go back to reference Cunha S, Santos AO, Menezes Correia JT, Sabino JR (2014) Formal aza-[3+3] versus aza-[3+2] cycloadditions of heterocyclic enaminones with maleic anhydride and maleimides: Skeletally diverse synthesis of pyrrolizidinones, indolizidinones, and pyrroloazepinones. Tetrahedron 70:3284–3290 Cunha S, Santos AO, Menezes Correia JT, Sabino JR (2014) Formal aza-[3+3] versus aza-[3+2] cycloadditions of heterocyclic enaminones with maleic anhydride and maleimides: Skeletally diverse synthesis of pyrrolizidinones, indolizidinones, and pyrroloazepinones. Tetrahedron 70:3284–3290
43.
go back to reference Allin SM et al (2007) A new asymmetric synthesis of the anti-tumor alkaloid ( R ) - ( + ) -Crispine A. J Org Chem 72:8972–8975PubMed Allin SM et al (2007) A new asymmetric synthesis of the anti-tumor alkaloid ( R ) - ( + ) -Crispine A. J Org Chem 72:8972–8975PubMed
44.
go back to reference Comins DL, Brooks CA, Ingalls CL, Carolina N (2001) Reduction of N-Acyl-2,3-dihydro-4-pyridones to N-Acyl-4-piperidones using zinc/acetic acid. J Org Chem 66:2181–2182PubMed Comins DL, Brooks CA, Ingalls CL, Carolina N (2001) Reduction of N-Acyl-2,3-dihydro-4-pyridones to N-Acyl-4-piperidones using zinc/acetic acid. J Org Chem 66:2181–2182PubMed
45.
go back to reference Padwa, A.. Sheehan, S. M and Straub, C. S. (1999). An Isomu1nchnone-based method for the synthesis of highly substituted 2(1H)-Pyridones, J Org Chem, 64: 8648–8659 Padwa, A.. Sheehan, S. M and Straub, C. S. (1999). An Isomu1nchnone-based method for the synthesis of highly substituted 2(1H)-Pyridones, J Org Chem, 64: 8648–8659
46.
go back to reference Wang M, Miao Chengb WY, Huang Z (1999) A systematic study of reaction of heterocyclic Enamines with electrophilic alkynes : A simple and efficient synthetic route to 2-Pyridinone-fused Heterocycles. Tetrahedron 55:14611–14622 Wang M, Miao Chengb WY, Huang Z (1999) A systematic study of reaction of heterocyclic Enamines with electrophilic alkynes : A simple and efficient synthetic route to 2-Pyridinone-fused Heterocycles. Tetrahedron 55:14611–14622
47.
go back to reference Cunha S, Damasceno F, Ferrari J (2007) New alkaloid-like heterocycles via formal aza-[3+2] cycloaddition reaction of cyclic enaminones with cyclopropenones. Tetrahedron Lett 48:5795–5798 Cunha S, Damasceno F, Ferrari J (2007) New alkaloid-like heterocycles via formal aza-[3+2] cycloaddition reaction of cyclic enaminones with cyclopropenones. Tetrahedron Lett 48:5795–5798
48.
go back to reference Cunha S, Kascheres A (2001) Reaction of Diphenylcyclopropenone with N-Acylamidine derivatives. Synthetic and mechanistic implications. J Braz Chem Soc 12:481–484 Cunha S, Kascheres A (2001) Reaction of Diphenylcyclopropenone with N-Acylamidine derivatives. Synthetic and mechanistic implications. J Braz Chem Soc 12:481–484
49.
go back to reference Grudzie M, Mazurek AP (2016) Cytisine basicity , solvation , log P , and log D theoretical determination as tool for bioavailability prediction. J Mol Graph Model 63:15–21 Grudzie M, Mazurek AP (2016) Cytisine basicity , solvation , log P , and log D theoretical determination as tool for bioavailability prediction. J Mol Graph Model 63:15–21
50.
go back to reference De Oliveira DM et al (2014) 8-Methoxypsoralen is a competitive inhibitor of glutathione. Front Cell Neurosci 8:1–11 De Oliveira DM et al (2014) 8-Methoxypsoralen is a competitive inhibitor of glutathione. Front Cell Neurosci 8:1–11
51.
go back to reference Yan B, Wang J, Liu L (2016) Chemotherapy promotes tumour cell hybridization in vivo. Tumor Biol 37:5025–5030 Yan B, Wang J, Liu L (2016) Chemotherapy promotes tumour cell hybridization in vivo. Tumor Biol 37:5025–5030
52.
go back to reference Chau DM, Teresa MD, Gilewski A, Antonella Surbone MD, Norton L (2003) Growth curve analysis, 6th edn. Holland-Frei Cancer Medicine, Hamilton BC Decker Chau DM, Teresa MD, Gilewski A, Antonella Surbone MD, Norton L (2003) Growth curve analysis, 6th edn. Holland-Frei Cancer Medicine, Hamilton BC Decker
53.
go back to reference Sekar TV, Paulmurugan R. (2014) Bioluminescence imaging of Cancer therapy. Elsevier Inc. Sekar TV, Paulmurugan R. (2014) Bioluminescence imaging of Cancer therapy. Elsevier Inc.
54.
go back to reference Bacevic K et al (1995) Spatial competition constrains resistance to targeted cancer therapy targeted cancer therapy. Nat Commun 8:1–15 Bacevic K et al (1995) Spatial competition constrains resistance to targeted cancer therapy targeted cancer therapy. Nat Commun 8:1–15
55.
go back to reference Longacre M, Snyder N, Sarkar S (2014) Drug resistance in Cancer : an overview. Cancers (Basel) 6:1769–1792 Longacre M, Snyder N, Sarkar S (2014) Drug resistance in Cancer : an overview. Cancers (Basel) 6:1769–1792
56.
go back to reference Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3:362–374PubMed Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3:362–374PubMed
57.
go back to reference Kerr JFR, Wyllie AH, Currie AR (1972) APOPTOSIS : A basic biological phenomenon with wide-ranging implication in tissue kinetics. Br J Cancer 26:239–257PubMedPubMedCentral Kerr JFR, Wyllie AH, Currie AR (1972) APOPTOSIS : A basic biological phenomenon with wide-ranging implication in tissue kinetics. Br J Cancer 26:239–257PubMedPubMedCentral
Metadata
Title
Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells
Authors
Mona Oliveira
Lourenço Luis Botelho de Santana
José Claudio Serafim
Airam Oliveira Santos
Michelle Pereira Quintino
José Tiago Menezes Correia
Fabiano Damasceno
José Ricardo Sabino
Thiago Rubens Cardim Pires
Paulo Lucas Cerqueira Coelho
Giselle Pinto de Faria Lopes
Henning Ulrich
Silvia Lima Costa
Silvio Cunha
Publication date
01-10-2020
Publisher
Springer US
Published in
Investigational New Drugs / Issue 5/2020
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-019-00877-2

Other articles of this Issue 5/2020

Investigational New Drugs 5/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine